As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by building a broad, durable intellectual property estate to anchor the next generation of non-hallucinogenic, neuroplasticity-enhancing medicines.
Just one day after announcing that it had retained legal heavyweight Fish & Richardson P.C. to defend its U.S. Patent No. 12,138,276 against a Post-Grant Review (PGR) challenge from Gilgamesh Pharmaceuticals, a company recently acquired by AbbVie, in a $1.2 billion transaction, Enveric is back in the news.
Today, the company announced the issuance of U.S. Patent No. 12,428,408, titled “Fused Heterocyclic Mescaline Derivatives.” This new patent marks the 23rd U.S. patent issued to Enveric and expands the company’s already impressive neuroplastogenic patent estate, now totaling 26 issued U.S. patents and 60 national and international pending applications.
According to Enveric, these compounds are designed to target key serotonin receptors and promote neuroplasticity, the brain’s ability to adapt and reorganize, without triggering hallucinations, offering a practical and scalable alternative to classical psychedelics.
“The issuance of this 23rd U.S. patent in Enveric’s neuroplastogenic patent estate demonstrates our continued momentum and commitment to the development of a strong intellectual property portfolio,” said Dr. Joseph Tucker, CEO of Enveric. “Our deep pipeline of next-generation molecules is designed to address significant unmet needs in mental health.”
Enveric’s lead candidate, EB-003, is a dual 5-HT2A/5-HT1B agonist designed to deliver durable antidepressant and anxiolytic effects without the hallucinogenic side effects that complicate clinical deployment of classical psychedelics like psilocybin and DMT.
While EB-003 is covered under a separate patent family (unrelated to the Gilgamesh dispute), the company’s proactive defense of its ‘276 patent, which includes claims that appear relevant to Bretisilocin (GM-2505), the very compound AbbVie is acquiring from Gilgamesh, signals how seriously Enveric takes its role as an innovator and protector of IP in this space.
Enveric has made it clear: it will vigorously defend its IP position, while continuing to expand its pipeline and out-license non-core programs, a strategy already generating up to $205 million in potential milestone payments and future royalties.
In a field often dominated by headlines around tripping, transformation, and celebrity-backed therapies, Enveric is taking a different route, one grounded in clinical practicality, patent protection, and scalable drug development.
With a first IND submission for EB-003 expected in early 2026, a robust patent estate spanning multiple compound classes, and a growing set of out-licensed assets, Enveric is looking less like a long shot, and more like the biotech many have underestimated.
As the psychedelic-inspired medicine space evolves from cultural curiosity to regulated care, the winners will be those who can scale, protect, and deliver. Enveric is quietly — but decisively — building that foundation.
